Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

Diabetes Care 2018 02 15;41(2):258-266. Epub 2017 Dec 15.

MedStar Health Research Institute, Hyattsville, MD.

Objective: To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes.

Research Design And Methods: In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. The primary end point was change from baseline in HbA at week 56.

Results: Mean HbA (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] -0.62% [95% CI -0.80, -0.44] [-6.78 mmol/mol (95% CI -8.70, -4.86)]; < 0.0001 for noninferiority and superiority). Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD -3.78 kg [95% CI -4.58, -2.98]; < 0.0001). Significantly more subjects treated with semaglutide (67%) achieved HbA <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%). Both treatments had similar safety profiles, but gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER-treated subjects (33.3%); injection-site reactions were more frequent with exenatide ER (22.0%) than with semaglutide (1.2%).

Conclusions: Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.

Download full-text PDF

Source
http://dx.doi.org/10.2337/dc17-0417DOI Listing
February 2018
25 Reads

Publication Analysis

Top Keywords

subjects type
12
semaglutide exenatide
12
type diabetes
8
efficacy safety
8
once-weekly semaglutide
8
baseline reduced
8
safety once-weekly
8
semaglutide
6
exenatide
6
100 mmol/mol
4
09% 100
4
mmol/mol semaglutide
4
168 mmol/mol
4
semaglutide 09%
4
treatment difference
4
exenatide [etd]
4
[etd] -062%
4
difference exenatide
4
15% 168
4
exenatide estimated
4

Similar Publications